Mert Başaran

Mert Başaran

Auto-generated profile, based on publicly available information

Mert Başaran

Institute of Oncology, Department of Oncology, Istanbul University, Istanbul, Turkey

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 February 2004 in International Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
HÖHarzem Özger
Harzem Özger
Levent EralpLevent Eralp
Levent Eralp
MTMehmet Türker
Mehmet Türker
MBMert Basaran
Mert Basaran

10 March 2025 in European Journal of Nuclear Medicine and Molecular Imaging
Verified
Journal Article
Open access
PDF file
ETEdanur Topal
Edanur Topal
BKBilal Kovan
Bilal Kovan
AÇAyça İribaş çelik
Ayça İribaş çelik
SKSerkan Kuyumcu
Serkan Kuyumcu
MBMert Basaran
Mert Basaran
YSYasemin Sanli
Yasemin Sanli
Purpose: This study aimed to evaluate the personalized dosimetric approach by calculating the cumulative renal absorbed dose (cRD) and assessing its impact on renal functions in patients diagnosed with metastatic castration-resistant prostate cancer who underwent four or more cycles of [177Lu] Lu-PSMA − 617 therapy. Methods: The study included 110 patients who received ≥ 4 cycles of [177Lu] Lu-PSMA − 617 therapy. Whole-body static and abdominal SPECT-CT imaging was performed at 4, 24, and 96 h post-administration. Kidney function was assessed using dynamic renal scintigraphy and biochemical tests conducted prior to treatment. Estimated glomerular filtration rate (eGFR) levels were calculated using the CKD-EPI formula before each treatment cycle and at the 6th week post-treatment. Results: Pearson correlation analysis reveal no significant relationship between cRD and CKD-EPI values (p >.05). No significant differences were observed between pre-treatment CKD-EPI levels and those measured after the 4th, 5th, 6th, 7th, and 8th cycles (p >.05). Among patients reaching a cRD of 23 Gy, a statistically significant difference was observed between pre- and post-treatment CKD-EPI values (p <.05). Of the 13 patients exceeding cRD of 28 Gy, five maintained CKD-EPI levels above 90 mL/min/1.73 m2 post-treatment. Conclusion: Despite treatment-related declines in eGFR levels, our findings indicate that a personalized dosimetric approach may enable extended cycles of [177Lu] Lu-PSMA-617 therapy with manageable nephrotoxicity. Considering the significant inter-patient variability, establishing universal absorbed dose-response relationships remains challenging. Prospective multicenter studies are crucial to refining toxicity thresholds and advancing tailored treatment strategies to optimize safety and efficacy.

19 October 2011 in Japanese Journal of Clinical Oncology
Verified
Journal Article
Open access
PDF file
IYIbrahim Yildiz
Ibrahim Yildiz
FSFatma Sen
Fatma Sen
MBMert Basaran
Mert Basaran
MEMeltem Ekenel
Meltem Ekenel
FAFulya Agaoglu
Fulya Agaoglu
SBSevil Bavbek
Sevil Bavbek
Therapy targeted against the vascular endothelial growth factor pathway is a standard of care for patients with metastatic renal cell carcinoma. This study assessed the response rates and toxicity profiles of sunitinib on a continuous once-daily dosing regimen in Turkish patients with metastatic renal cell carcinoma. Between April 2006 and August 2010, 74 patients with metastatic renal cell carcinoma who received sunitinib on a continuous, once-daily dosing regimen were included. Sunitinib was administered daily at a dose of either 37.5 mg (94% of the patients) or 25 mg (6% of the patients), without interruption, either as a second-line treatment after interferon-α or as a first-line treatment. Response, toxicity, progression-free survival and overall survival were evaluated. Of the 74 patients, 65 (88%) were diagnosed with clear cell renal cell carcinoma. The median treatment duration was 10 months (range, 2–42 months). The most common treatment-related adverse events were fatigue (75%), stomatitis (51%) and hypertension (50%). The most common Grade 3 or 4 adverse events were anemia (10%) and hand–foot syndrome (7%). Dose reductions were required in 50% of the patients, and early treatment discontinuation was necessary in 16% of the patients. Cardiovascular events were the most common adverse events that resulted in drug discontinuation. The objective response rate and the disease control rate were 30 and 78%, respectively. The median progression-free survival and overall survival were 13 and 25 months, respectively. Continuous, once-daily administration of sunitinib was generally well tolerated in Turkish patients with advanced renal cell carcinoma in a daily practice setting. This study's response rates were comparable to those in previous randomized trials.

27 July 2022 in Journal of Chemotherapy
Verified
Journal Article
Closed access
IDIzzet Dogan
Izzet Dogan
AIAyca Iribas
Ayca Iribas
MAMelin Aydan Ahmed
Melin Aydan Ahmed
MBMert Basaran
Mert Basaran
The goal of the research was to investigate if a combination of vincristine, irinotecan and temozolomide (VIT) could benefit adult patients with metastatic Ewing sarcoma who had already been heavily pretreated. Metastatic Ewing sarcoma patients had their data retrospectively analyzed. The patients' clinical, radiological and therapeutic data were recorded. Survival analyzes were performed with these data. The study enlisted the participation of sixteen patients. The average age was 25 years old (range: 20–42). The lung was the most prevalent metastatic location (81.3%). Patients had received at least two distinct chemotherapy combinations (87.5%) and palliative radiotherapy (37.5%) before receiving the (VIT) combination. The Median progression-free survival time was found as 3.4 (95% CI, 1.8–4.9) months. Five patients (31.3%) experienced a partial response, while the remaining patients (68.7%) had progressing disease. Thirteen individuals (81.3%) had grade 1–2 adverse events, whereas five (31.3%) had grade 3–4 adverse events. Hematological complications were the most common side effects (87.5%). Median overall survival was calculated as 5.6 (95% CI, 3.6–7.5) months in the patients after the beginning of VIT regimen. We demonstrated the efficacy of the VIT regimen in adult patients with metastatic Ewing sarcoma in this research. In these extensively pretreated patients, toxicities were a concern. Metastatic Ewing sarcoma patients have few treatment choices. In patients who have had a good performance status, VIT regimen may be considered for disease control.

21 May 2023 in Journal of Chemotherapy
Verified
Journal Article
Closed access
KTKübra Özkaya Toraman
Kübra Özkaya Toraman
RMRasim Meral
Rasim Meral
AKAhmet Nafiz Karadeniz
Ahmet Nafiz Karadeniz
GKGizem Kaval
Gizem Kaval
MBMert Başaran
Mert Başaran
MAMusa Altun
Musa Altun
This is the report on our clinic's 15 years of experience (2004-2018) on nasopharyngeal carcinoma (NPC), treated with induction chemotherapy (IC) and subsequent concomitant chemoradiotherapy (CCRT), comprising population characteristics and treatment outcomes of 203 patients with non-metastatic NPC. IC comprised docetaxel (75 mg/m2) and cisplatin (75 mg/m2) combination (TP). Concurrent cisplatin (P) was applied either weekly (40 mg/m2, 32 cases) or every-3-week (100 mg/m2, 171 cases). The median follow-up duration was 85 months (range, 5-204 months). Overall and distant failure rates were observed in 27.1% (n = 55) and 13.8% (n = 28) patients, respectively. The 5-year locoregional recurrence-free survival (LRRFS), distant metastasis-free survival (DMFS), disease-free survival (DFS), and overall survival (OS) rates were 84.1%, 86.4%, 75%, and 78.7% respectively. The overall stage was an independent prognostic factor for the LRRFS, DMFS, DFS, and OS. The WHO histological type was a prognostic factor for the LRRFS, DFS, and OS. Age was a prognostic factor for the DMFS, DFS, and OS. Concurrent P schedule was independent prognostic only the LRRFS.

1 January 2011 in Onkologie
Verified
Journal Article
Open access
PDF file
SUSelma Ugurel
Selma Ugurel
HKHossein Khedmat
Hossein Khedmat
AHAlan Horwich
Alan Horwich
PBPierluigi Brugnaro
Pierluigi Brugnaro
EMErika Morelli
Erika Morelli
CKClaus-Henning Köhne
Claus-Henning Köhne